p53-MDM2-IN-6, with the CAS number 1054506-59-0, is a small molecule inhibitor designed to target the interaction between the p53 tumor suppressor protein and the MDM2 oncoprotein. This interaction is crucial in regulating the p53 pathway, which plays a significant role in cell cycle control, apoptosis, and DNA repair. The compound is characterized by its ability to disrupt the p53-MDM2 binding, thereby stabilizing p53 and promoting its tumor-suppressive functions. It is typically studied in the context of cancer therapeutics, particularly for tumors that exhibit MDM2 overexpression, which can lead to the inactivation of p53. The compound's efficacy and specificity are often evaluated through various biochemical assays and cellular models. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are critical for assessing its potential as a therapeutic agent. Overall, p53-MDM2-IN-6 represents a promising avenue for cancer treatment by reactivating the p53 pathway in malignancies where it is compromised.

p53-MDM2-IN-6

1054506-59-0: p53-MDM2-IN-6, with the CAS number 1054506-59-0, is a small molecule inhibitor designed to target the interaction between the p53 tumor suppressor protein and the MDM2 oncoprotein. This interaction is crucial in regulating the p53 pathway, which plays a significant role in cell cycle control, apoptosis, and DNA repair. The compound is characterized by its ability to disrupt the p53-MDM2 binding, thereby stabilizing p53 and promoting its tumor-suppressive functions. It is typically studied in the context of cancer therapeutics, particularly for tumors that exhibit MDM2 overexpression, which can lead to the inactivation of p53. The compound's efficacy and specificity are often evaluated through various biochemical assays and cellular models. Additionally, its pharmacokinetic properties, such as absorption, distribution, metabolism, and excretion (ADME), are critical for assessing its potential as a therapeutic agent. Overall, p53-MDM2-IN-6 represents a promising avenue for cancer treatment by reactivating the p53 pathway in malignancies where it is compromised.

p53-MDM2-IN-6, an LSM-83177 hydrazone analog, acts as an efficacious p53-MDM2 inhibitor with an IC50 of 11.08 µg/mL. This compound inhibits the p53-MDM2 interaction leading to an increase in p-53 levels while concurrently decreasing GST enzyme expression. It halts the cell cycle at the S phase and induces early and late apoptosis (Apoptosis), exhibiting antiproliferative activity against the HT29 cell line with an IC50 of 10.44 µg/mL. p53-MDM2-IN-6 holds promise for research in colorectal cancer.

CAS 1054506-59-0

p53-MDM2-IN-6

p53-MDM2-IN-6

Ref: TM-T200473